Key Results:
Mice administered C-176 had significantly smaller cortical lesion area
when compared to vehicle-treated mice 24h post-TBI. Quantitative
temporal gait analysis conducted using DigiGait™ showed C-176
administration attenuated TBI-induced impairments in gait symmetry,
stride frequency and forelimb stance width. C-176-treated mice displayed
a significant reduction in striatal gene expression of pro-inflammatory
cytokines TNF-α, IL-1β and CXCL10 compared to their vehicle-treated
counterparts 2h post-TBI.